We are supported by
Cell therapy in solid tumours has a long list of documented failures. We treat that list as a specification — and we hold every decision to the same bar before it moves forward.
Each barrier below is a documented failure mode in the field. For each, the platform carries a deliberate engineering answer — described here at the level of intent and outcome, not mechanism.
Failure mode: engineered cells never reach the tumour bed.
Engineered answerA navigation system that directs the cell toward the tumour.
Failure mode: the hostile microenvironment locks cells out.
Engineered answerA solid-tumour breaker that gets inside and survives entry.
Failure mode: cells exhaust before the job is done.
Engineered answerIntrinsic durability that sustains activity over time.
Failure mode: toxicity forces costly inpatient management.
Engineered answerAutonomous safety designed for the outpatient setting.
A candidate decision is not “promising” until it reads out across all five dimensions. This is how we keep conviction honest and avoid optimising one axis at the expense of the others.
Does the engineering translate into a real, repeatable effect against the target?
Is the response controllable, with a tolerability profile fit for outpatient care?
Can it be made reproducibly at the quality the rest of the plan assumes?
Does the cost structure support a sustainable, scalable therapy?
Could it realistically reach the patients who need it, not just a few centres?
Our design choices are triangulated against publicly established results in cell therapy. Where we cite a precedent, we cite it accurately and at the level the public record supports.
Engineered T-cell therapy is an established, approved modality in haematological cancers — the foundation we build on.
The barriers we target are documented across the public literature as the reasons solid-tumour translation has lagged.
Toxicity management is a known driver of where and how cell therapy is delivered — and therefore of access.
We are not learning cell therapy on this asset.— The Gaisce operating principle
We are supported by